Please login to the form below

Not currently logged in
Email:
Password:

JAK2 inhibitor

This page shows the latest JAK2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

CTI slumps as Servier-partnered lymphoma drug fails

CTI slumps as Servier-partnered lymphoma drug fails

Thankfully for CTI, it’s been making progress on main pipeline candidate pacritinib, an orally-active kinase inhibitor that targets JAK2, FLT3, IRAK1 and CSF1R and is in phase III testing

Latest news

  • Another R&D flop for Incyte, but Jakafi keeps delivering Another R&D flop for Incyte, but Jakafi keeps delivering

    Incyte is still trying to recover from the mauling it took after its IDO inhibitor epacadostat for cancer failed earlier this year, and yesterday wrote off another programme in ... JAK1/JAK2 inhibitor Jakafi – given in combination with corticosteroids

  • Is acquisitive Celgene now eyeing CAR-T specialist Juno? Is acquisitive Celgene now eyeing CAR-T specialist Juno?

    The rumours have started circulating just a few days after Celgene agreed a deal to acquire San Diego-based start-up Impact Bio, adding to its haematology business with a JAK2 ... inhibitor - fedratinib - in development for myelofibrosis and

  • Celgene boosts haematology pipeline with $7bn Impact Bio deal Celgene boosts haematology pipeline with $7bn Impact Bio deal

    The US biotech is spending $1.1bn in upfront cash to buy Impact Bio and its late-stage drug candidate fedratinib, a JAK2 inhibitor in development for myelofibrosis and polycythaemia vera ... to Incyte and Novartis’rival JAK inhibitor Jakafi (ruxolitinib

  • Lilly planning 20 new launches by 2023 Lilly planning 20 new launches by 2023

    The selective JAK1 and JAK2 inhibitor is being co-developed with Incyte and heads up "a robust emerging pipeline of both internal assets and partnered molecules focusing on key pathways and ... Pfizer-partnered NGF inhibitor tanezumab for osteoarthritis

  • Incyte abandons solid tumour programme for Jakafi Incyte abandons solid tumour programme for Jakafi

    In the JANUS 1 trial, JAK1/JAK2 inhibitor Jakafi (ruxolitinib) failed to show a significant benefit when given alongside Roche's Xeloda (capecitabine) as a second-line treatment for patients with ... Incyte said that a phase II trial in pancreatic cancer

More from news
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    The headline value contains significant sales milestones linked to performance of Impact's lead phase III stage asset fedratinib, an oral JAK2 kinase inhibitor in development for the treatment of myelofibrosis ... Acquisition company - remaining 90%. 9,

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    232. Cell Therapeutics / Baxter. Licence. JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase.

  • Pharma deals during November 2013 Pharma deals during November 2013

    While Sanofi announced this month that it had discontinued clinical trials of fedratinib (SAR302503), an investigational JAK2 inhibitor, Baxter entered an exclusive global agreement (headline value $172m) to develop and commercialise ... Cell Therapeutics

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics